

**Preferred Drug List Committee
Meeting Agenda, Open Session
March 11, 2020 11:30am to 1:00pm**

Meeting Location

DXC Technology (formerly HP Enterprise Services) Capital Room
6511 SE Forbes Ave., Bldg. 283 J, Topeka, Kansas 66619

Committee Members

Jessica Bates, PharmD., BCPS	Megan Hedden, PharmD.
Emily Blew, PharmD.	William Pankey, M.D.
Taylor Gill, PharmD., BCPS	James Rider, D.O.
Katherine Grimsley, M.D.	Donna Sweet, M.D.
Robert Haneke, Pharm.D.	Wayne Wallace, M.D.

KDHE-DHCF/Contractor Staff

Annette Grant, RPh	Markie O'Donnell, Transcriptionist
Victor Nguyen, Pharm.D.	

DXC Technology Staff

Karen Kluczykowski, RPh.	Kathy Kaesewurm, RN, BSN
--------------------------	--------------------------

- I. Call to Order
 - a. Announcements and Introductions
- II. Review & Approval of Meeting Minutes from 09/11/2019
- III. Old Business
 - a. Consent Agenda Items
 - i. PDL New Drug Placements
 - 1. Arazlo™ Lotion
 - 2. Conjupri® Tablets
 - 3. Drizalma Sprinkle®
 - 4. Harvoni® Pellets
 - 5. Ipratropium Bromide 0.02% Inhalation Solution.
 - 6. ProAir Digihaler®
 - 7. RediTrex™ Injection
 - 8. Riomet ER™ Suspension
 - 9. Solvaldi® Pellets
 - 10. Zyrtec ODT/CT®

- ii. Committee discussion/Recommendations

IV. New Business

a. New Drug Classes

- i. Acne Agents – Isotretinoin Products – (Absorica®, Absorica® LD, Accutane®, Amnesteem®, Claravis®, Myorisan®, Sotret®, Zenatane®)
 - 1. Public Comment
 - 2. Committee Discussion/Recommendations
- ii. Colchicine Products – Prophylaxis (Colcrys™, Gloperba®, Mitigare™)
 - 1. Public Comment
 - 2. Committee Discussion/Recommendations
- iii. SGLT2 Inhibitor/DPP-4 Inhibitor/Biguanide Combination Agents – (Qternmet® XR, Trijardy™ XR)
 - 1. Public Comment
 - 2. Committee Discussion/Recommendations

b. New Drugs to Existing Classes

- i. Anti-Constipation Agents – Class Review – New Agent: (Motegrity™)
 - 1. Public Comment
 - 2. Committee Discussion/Recommendations
- ii. Beta2-Agonist – Long-Acting/Anticholinergics Agents – Class Review – New Agent: (Duaklir® Pressair®)
 - 1. Public Comment
 - 2. Committee Discussion/Recommendations
- iii. Immunomodulation Agents – Adult Rheumatoid Arthritis – Class Review – New Agents: (Abrilada®, Amjevita™, Avsola®, Cyltezo®, Erelzi®, Eticovo®, Hadlima™, Rinvoq™, Truxima®)
 - 1. Public Comment
 - 2. Committee Discussion/Recommendations
- iv. Immunomodulation Agents – Ankylosing Spondylitis – Class Review – New Agents: (Abrilada®, Amjevita™, Avsola®, Cyltezo®, Erelzi®, Eticovo®, Hadlima™, Simponi Aria®)
 - 1. Public Comment
 - 2. Committee Discussion/Recommendations
- v. Immunomodulation Agents – Crohn's Disease – Class Review – New Agents: (Abrilada®, Amjevita™, Avsola®, Cyltezo®, Hadlima™)
 - 1. Public Comment
 - 2. Committee Discussion/Recommendations

- vi. Immunomodulation Agents – Juvenile Idiopathic Arthritis – Class Review – New Agents: (Abrilada®, Amjevita™, Cyltezo®, Erelzi®, Eticovo®, Hadlima™)
 - 1. Public Comment
 - 2. Committee Discussion/Recommendations
- vii. Immunomodulation Agents – Plaque Psoriasis – Class Review – New Agents: (Abrilada®, Amjevita™, Avsola®, Cyltezo®, Erelzi®, Eticovo®, Hadlima™, Skyrizi™)
 - 1. Public Comment
 - 2. Committee Discussion/Recommendations
- viii. Immunomodulation Agents – Psoriatic Arthritis – Class Review – New Agents: (Abrilada®, Amjevita™, Avsola®, Cyltezo®, Erelzi®, Eticovo®, Hadlima™, Simponi Aria ®)
 - 1. Public Comment
 - 2. Committee Discussion/Recommendations
- ix. Immunomodulation Agents – Ulcerative Colitis – Class Review – New Agents: (Abrilada®, Amjevita™, Avsola®, Cyltezo®, Hadlima™, Stelara®, Xeljanz® XR)
 - 1. Public Comment
 - 2. Committee Discussion/Recommendations
- x. Approval to add biosimilars for the same indication(s) as the reference product in the Consent Agenda Item approval process.
 - 1. Public Comment
 - 2. Committee Discussion/Recommendations

V. Open Public Comment

VI. Adjourn

****THIS AGENDA IS SUBJECT TO CHANGE****